Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 23, 2012

EntreMed Raises $10M To Progress Clinical Anticancer Pipeline and Expand R&D

  • EntreMed raised $10 million through the issuance of convertible notes to accredited investors. The firm says it will use the proceeds, estimated at about $9.3 million net, to expand its R&D activities, fund new clinical trials, and initiate new initiatives and long-term strategic plans.

    EntreMed is a clinical-stage pharmaceutical company focused on the treatment of cancer and inflammatory diseases. The firm’s oral oncology candidates are designed to inhibit multiple pathways that promote the formation and replication of tumor cells, while interrupting the formation of tumor-feeding blood vessels.

    Lead candidate ENMD-2076 is an orally active Aurora A/angiogenic kinase inhibitor, which has completed Phase I studies in patients with solid tumors and leukemia, and is currently undergoing Phase II evaluation in ovarian cancer, and Phase I testing against multiple myeloma. Positive progression-free survival data from a Phase II study evaluating ENMD-2076 monotherapy in patients with platinum-resistant ovarian cancer was reported in October 2011. 

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »